Profile data is unavailable for this security.
About the company
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
- Revenue in USD (TTM)0.00
- Net income in USD-2.45bn
- Incorporated2015
- Employees159.00
- LocationVor Biopharma Inc500 Boylston Street, Suite 1350BOSTON 02116United StatesUSA
- Phone+1 (617) 655-6580
- Fax+1 (302) 655-5049
- Websitehttps://www.vorbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verastem Inc | 13.38m | -241.11m | 513.08m | 78.00 | -- | -- | -- | 38.35 | -4.02 | -4.02 | 0.2209 | -0.2326 | 0.0882 | -- | 3.76 | 171,525.60 | -159.03 | -68.26 | -233.92 | -83.33 | 85.14 | -- | -1,802.12 | -417.53 | 2.55 | -- | 1.21 | -- | -- | -10.54 | -49.53 | -- | 31.95 | -- |
| Regenxbio Inc | 161.32m | -177.92m | 521.92m | 353.00 | -- | 3.23 | -- | 3.24 | -3.46 | -3.46 | 3.14 | 3.19 | 0.3089 | -- | 6.59 | 456,991.50 | -34.07 | -20.33 | -43.55 | -23.79 | 87.18 | 76.64 | -110.29 | -82.78 | -- | -6.74 | 0.5427 | -- | -7.66 | 18.79 | 13.81 | -- | -26.96 | -- |
| Gossamer Bio Inc | 44.05m | -156.16m | 523.09m | 144.00 | -- | -- | -- | 11.87 | -0.6872 | -0.6872 | 0.1939 | -0.356 | 0.1574 | -- | 5.57 | 305,909.70 | -55.80 | -51.30 | -69.95 | -58.28 | -- | -- | -354.50 | -822.21 | -- | -15.04 | 1.71 | -- | -- | -- | 68.56 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -62.26m | 523.16m | 76.00 | -- | 4.10 | -- | -- | -2.31 | -2.31 | 0.00 | 4.11 | 0.00 | -- | -- | 0.00 | -36.77 | -- | -39.46 | -- | -- | -- | -- | -- | -- | -- | 0.1675 | -- | -- | -- | -69.21 | -- | -- | -- |
| Lexicon Pharmaceuticals Inc | 70.86m | -68.58m | 523.95m | 103.00 | -- | 3.63 | -- | 7.39 | -0.1894 | -0.1894 | 0.1954 | 0.3307 | 0.2689 | 1.06 | 27.10 | 688,000.00 | -26.02 | -55.75 | -29.23 | -66.32 | 99.41 | 95.36 | -96.77 | -1,103.37 | 5.63 | -6.58 | 0.3199 | -- | 2,481.48 | -37.35 | -13.15 | -- | 71.25 | -- |
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 525.51m | 72.00 | -- | 3.27 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Altimmune Inc | 20.00k | -83.92m | 529.19m | 59.00 | -- | 2.42 | -- | 26,459.48 | -1.07 | -1.07 | 0.0003 | 1.94 | 0.0001 | -- | 0.0314 | 338.98 | -45.82 | -42.36 | -48.64 | -45.46 | -- | -- | -419,575.00 | -3,193.88 | -- | -- | 0.0722 | -- | -95.31 | -67.83 | -7.48 | -- | -- | -- |
| Keros Therapeutics Inc | 246.72m | 64.45m | 534.07m | 82.00 | 11.36 | 1.01 | 8.11 | 2.16 | 1.54 | 1.54 | 6.07 | 17.32 | 0.3732 | -- | 127.17 | 1,459,870.00 | 9.75 | -36.26 | 10.16 | -38.17 | -- | -- | 26.12 | -2,307.89 | -- | -- | 0.00 | -- | 2,250.99 | -18.71 | -22.46 | -- | 48.10 | -- |
| Solid Biosciences Inc | 0.00 | -167.14m | 534.46m | 100.00 | -- | 2.45 | -- | -- | -2.49 | -2.49 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -68.82 | -47.92 | -78.37 | -53.98 | -- | -- | -- | -2,151.47 | -- | -- | 0.0013 | -- | -- | -- | -29.87 | -- | -31.66 | -- |
| Evommune Inc | 3.00m | -66.26m | 535.59m | 45.00 | -- | -- | -- | 178.53 | -2.20 | -2.20 | 0.0997 | 2.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2,158.80 | -- | -- | -- | 0.0086 | -- | 40.00 | -- | -100.59 | -- | -- | -- |
| Vor Biopharma Inc | 0.00 | -2.45bn | 546.82m | 159.00 | -- | -- | -- | -- | -386.85 | -386.85 | 0.00 | -246.54 | 0.00 | -- | -- | 0.00 | -1,676.47 | -49.21 | -1,891.22 | -52.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8052 | -- | -21.08 | -- |
| Perspective Therapeutics Inc | 1.08m | -106.31m | 551.34m | 138.00 | -- | 1.49 | -- | 512.88 | -1.46 | -1.46 | 0.0147 | 3.26 | 0.0031 | -- | 5.43 | 7,789.86 | -31.00 | -- | -33.37 | -- | -- | -- | -9,889.68 | -- | -- | -- | 0.0067 | -- | 1.39 | -- | -109.13 | -- | -- | -- |
| Contineum Therapeutics Inc | 0.00 | -59.39m | 557.80m | 41.00 | -- | 2.47 | -- | -- | -2.26 | -2.26 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -29.19 | -- | -30.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -285.99 | -- | -- | -- |
| Ginkgo Bioworks Holdings Inc | 180.61m | -339.55m | 584.54m | 834.00 | -- | 1.03 | -- | 3.24 | -6.22 | -6.22 | 3.31 | 9.85 | 0.1353 | -- | 7.80 | 216,554.00 | -25.43 | -68.97 | -27.83 | -75.53 | 72.71 | 66.73 | -188.00 | -409.12 | -- | -- | 0.00 | -- | -9.71 | 33.18 | 38.73 | -- | 23.00 | -- |
| Design Therapeutics Inc | 0.00 | -67.45m | 591.28m | 55.00 | -- | 2.96 | -- | -- | -1.19 | -1.19 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -28.49 | -18.88 | -29.66 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Vor Biopharma Inc's reporting currency: US Dollar USD
40.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 18 Dec 2025 | 5.40m | 13.96% |
| Paradigm BioCapital Advisors LPas of 11 Nov 2025 | 1.75m | 4.52% |
| Great Point Partners LLCas of 10 Dec 2025 | 1.23m | 18.05% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 669.84k | 1.73% |
| UBS Securities LLCas of 31 Dec 2025 | 245.22k | 0.63% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 232.96k | 0.60% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 93.84k | 0.24% |
| Tang Capital Management LLCas of 30 Sep 2025 | 50.00k | 0.13% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 46.90k | 0.12% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 34.33k | 0.09% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
